By Huldah Shado
A landmark agreement is set to transform HIV prevention in low- and middle-income countries, with generic versions of the injectable drug lenacapavir to be made available for just $40 per year starting in 2027, Unitaid and the Bill and Melinda Gates Foundation announced on Wednesday.
The twice-yearly injection marketed in the United States as Yeztugo by Gilead Sciences, has been shown to reduce HIV transmission risk by more than 99.9 percent. While the drug currently costs about $28,000 annually in the U.S., the rollout of generics is expected to significantly expand global access.
Unitaid confirmed partnerships with Dr. Reddy’s Laboratories, the Clinton Health Access Initiative (CHAI), and Wits RHI to deliver the treatment in 120 countries.
“The product will initially be manufactured in India, but we are also working toward regional production in the future,” said Carmen Perez Casas, Unitaid’s strategic lead for HIV.
The Gates Foundation separately announced a deal with Indian pharmaceutical company Hetero to ensure wide distribution.
“Scientific advances like lenacapavir can help us end the HIV epidemic, if they are made accessible to people who can benefit from them the most,” said Trevor Mundel, the foundation’s head of global health.
Although global HIV infections have declined by 40 percent since 2010, UNAIDS data shows 1.3 million people contracted the virus in 2024.
Advocates stress that affordable generics such as lenacapavir are essential to sustaining progress.
While the $40 generics are expected from 2027, Gilead has also signed an agreement with the Global Fund to expand access in low-income countries in the short term.
The U.S. government has reaffirmed support for the initiative, ensuring funding was preserved despite proposed foreign aid cuts under President Donald Trump.
The first batches of Yeztugo are expected to be delivered to at least one African country before the end of this year.